In last trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 5.65 million shares changing hands with its beta currently measuring 1.07. Company’s recent per share price level of $3.36 trading at $0.17 or 5.33% at ring of the bell on the day assigns it a market valuation of $1.10B. That closing price of IOVA’s stock is at a discount of -323.51% from its 52-week high price of $14.23 and is indicating a premium of 19.64% from its 52-week low price of $2.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.53 million shares which gives us an average trading volume of 9.69 million if we extend that period to 3-months.
For Iovance Biotherapeutics Inc (IOVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.31. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Upright in the green during last session for gaining 5.33%, in the last five days IOVA remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $3.36 price level, adding 2.04% to its value on the day. Iovance Biotherapeutics Inc’s shares saw a change of -54.59% in year-to-date performance and have moved 9.45% in past 5-day. Iovance Biotherapeutics Inc (NASDAQ:IOVA) showed a performance of -3.45% in past 30-days. Number of shares sold short was 75.19 million shares which calculate 6.61 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 44.0% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -78.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.57% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.17% during past 5 years.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.63% of company’s total shares while institution are holding 83.43 percent of that, with stock having share float percentage of 83.96%. Investors also watch the number of corporate investors in a company very closely, which is 83.43% institutions for Iovance Biotherapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IOVA for having 25.95 million shares of worth $208.12 million. And as of 2024-06-30, it was holding 9.1113 of the company’s outstanding shares.
The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 25.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1052 of outstanding shares, having a total worth of $207.98 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 8.61 shares of worth $28.93 million or 2.63% of the total outstanding shares. The later fund manager was in possession of 7.28 shares on Mar 31, 2025 , making its stake of worth around $24.47 million in the company or a holder of 2.22% of company’s stock.
